Shortwave Life Sciences Plc

🚀 @ShortwavePLC Digital Asset Treasury Update In one of the most volatile quarters the digital asset market has ever seen, capital preservation mattered more than speculation — and discipline paid off. 📉 While Q4 2025 saw: •#Bitcoin correct ~25% •Tech-correlated and leveraged proxies fall 50%+ •Widespread double-digit drawdowns across digital assets ✅ #PSY treasury drawdown to ~5% This wasn’t luck. It was strategy. 🛡️ By delaying deployment, focusing on liquidity (BTC, ETH, SOL), and treating the treasury as a utility — not a gamble — Shortwave preserved shareholder value and effectively retained ~20% of upside optionality for the recovery. 💬 “Q4 was a stress test for corporate digital treasuries. Our approach validated the importance of patience, discipline, and fiduciary focus.” — Stephen Molloy, Executive Director 🔮 Looking into 2026 Digital assets are evolving beyond speculation — driven by regulation, adoption, and integration into global financial systems. With liquidity preserved and risk managed, Shortwave is now well-positioned to scale into this structural shift while maintaining rigorous governance. 📊 Defensive when it mattered. 📈 Ready when opportunity returns. 🧬 Treasury strategy aligned with long-term life sciences innovation. #DigitalAssets #TreasuryStrategy #CapitalPreservation #LifeSciences #Bitcoin #Ethereum #Web3 #RiskManagement #2026Outlook

This confidence is not driven by short-term market movements, but by a clear structural shift that took place throughout 2025, as digital assets moved from a period of regulatory uncertainty into one of formal integration. Learn more: investors.shortwavelifesciences.com/?utm_source=Kl… #PSY

Why We Are Optimistic About Our Digital Asset Strategy We are increasingly confident in the role our digital asset strategy can play within Shortwave’s broader capital framework.

We’re pleased to announce the launch of a dedicated Investor Resources section on our official website. 🎉 Explore it here: buff.ly/Np3sTog #PSY

The past year was about building the foundations. This year is about execution. Learn more below 👇 #PSY @Share_Talk

🚀 Shortwave Life Sciences enters 2026 with momentum 2025 was about foundations for @ShortwavePLC but 2026 is about execution for #PSY 🧠 Strong clinical visibility following PSYCH Symposium, with renewed focus on evidence-led innovation in eating disorders 💊 Regulatory tailwinds as US cannabis rescheduling opens clearer FDA pathways 📈 Buccal film delivery technology increasingly positioned for CNS and cannabinoid therapies 🔗 Disciplined digital asset strategy strengthening long-term capital resilience under Stephen Molloy Measured optimism. Clear direction. Growing momentum. #LifeSciences #Biotech #MentalHealth #CNS #CapitalStrategy

This new hub has been created to give current and prospective investors a deeper view into Shortwave’s strategy, market opportunity, unique scientific approach & pipeline progress. #PSY

Investor Newsletter: Stay informed with the latest updates and announcements i 2026 from Shortwave Life Sciences. 📩 Subscribe by visiting the contact page and signing up at the bottom: shortwavelifesciences.com/contact/ #PSY

We’re building a new approach to treating eating disorders. A clinical-stage neuropsychiatry company combining innovative CNS therapies, a proprietary buccal film platform, and a forward-thinking digital asset strategy. Learn more here: investors.shortwavelifesciences.com/research #PSY

Shortwave Life Sciences mentioned as one of the ‘10 companies to follow in 2026’ by @TMSreach Read the full feature below 👇 #PSY

Shortwave Life Sciences: 2026 Outlook for Dual-Engine Strategy @StockBoxMedia spoke to Stephen Molloy and Ron Lipsky, Executive Director and Non-Executive Director of @ShortwavePLC (AQSE: PSY), to discuss the company’s dual-focus strategy and outlook for 2026. Watch below ⬇ youtu.be/GtnOBl3BxYY?si… ➡ Shortwave is progressing a novel treatment for anorexia nervosa, targeting a 2026 human efficacy trial - an important milestone in an area with no approved medical therapies. ➡ The company has launched a carefully managed digital asset treasury anchored by Bitcoin and guided by regulated partners to hedge against inflation and support funding needs. ➡ With operations in both life sciences and digital asset finance, Shortwave aims to demonstrate the strength of its dual-engine model through clinical and financial performance in 2026.

A Dreaded Season for Anorexia Sufferers – @ShortwavePLC Radical New Hope   “…this game-changing treatment…” Here, @copytaster speaks to #PSY Chief Medical Advisor Dr Nadya Lisodover and NED Ron Lipsky to find out more 🎙️ total-market-solutions.com/2025/12/shortw…

'Can Psilocybin Be Safe and Effective for Anorexia? Shortwave Life Sciences Is Leading a Study To Find Out' Following the @PSYCHSymposium Dr. Nadya Lisovoder outlines #PSY integrated, multi-pathway approach where traditional therapies fall short. Read: buff.ly/8H2FXbC

@ShortwavePLC (AQSE: #PSY) will serve as a Gold Partner at the @PSYCHSymposium on December 4, 2025. During the event, Chief Medical Advisor Dr. Nadya Lisovoder is set to share new clinical insights from a human study focused on anorexia treatment, detailing the rationale behind the company’s feasibility work on psychedelic-assisted therapy for severe anorexia nervosa and early results from its psilocybin-based buccal film program. The company’s involvement highlights its commitment to research that deepens scientific understanding and supports future regulatory evaluation, placing Shortwave among the organisations driving progress in psychedelic-based therapeutics. @RolfGerri share-talk.com/shortwave-life… via @Share_Talk

Shortwave Life Sciences to Present at @PSYCHSymposium London 2025 as Gold Partner 🌟 Fantastic that @ShortwavePLC will participate as a Gold Partner at the PSYCH Symposium on 4 December 2025, one of the world’s leading forums for scientific and clinical insight into psychedelic-based treatments. As part of the official agenda, Dr Nadya Lisovoder, the #PSY Chief Medical Advisor, will deliver: Designing Breakthroughs: A New Human Study for Anorexia Treatment, outlining the scientific rationale behind our feasibility study assessing psychedelic-assisted therapy for severe anorexia nervosa — a condition with some of the highest mortality rates in mental health and limited effective treatment options. Dr Lisovoder will also join Kate Spicer (The Sunday Times) for a discussion on the clinical and regulatory barriers that have slowed innovation in anorexia treatment, and how emerging research may change the landscape for patients and families. #PSY involvement in PSYCH reflects Shortwave’s commitment to rigorous clinical science, regulatory-focused research, and the development of next-generation mental health treatments. The Symposium brings together global leaders in neuroscience, psychiatry, policy and translational research — an ideal platform to share our direction and deepen collaboration. Rolf Gerritsen, Director of #Shortwave Life Sciences, commented: “Our participation places Shortwave among the organisations shaping the next phase of psychedelic medicine. This is an important step in progressing our scientific programme.” The Company also look forward to welcoming colleagues and partners at their Shortwave-hosted drinks reception following the close of the Symposium. 👉 Join them at PSYCH Symposium London 2025 as they continue to advance science for patients who need new therapeutic pathways. #ShortwaveLifeSciences #PSYCH2025 #ClinicalResearch #PsychedelicMedicine #AnorexiaTreatment #MentalHealthInnovation #LifeSciences #Biotech #HealthcareLeadership

@PSYCHSymposium is a leading international forum bringing together top clinicians, neuroscientists and policy experts to discuss emerging data, regulation and patient access in psychedelic-based treatments. #PSY

Shortwave Life Sciences will be a Gold Partner at the @PSYCHSymposium on 4 Dec 2025 at London’s Conway Hall. 🎉 Read more here: aquis.eu/stock-exchange… #PSY

Shortwave Life Sciences announces all AGM resolutions were passed and issues a correction to share capital statistics. Post-consolidation share capital is 54,260,677 Ordinary Shares and 54,260,677 Deferred Shares. 🔗 aquis.eu/stock-exchange… #PSY